浙江医学2011，Vol.33Issue(7)：1020-1023,1110,5.
瑞舒伐他汀对LDL受体基因缺陷小鼠MMP-2表达和粥样斑块形成的抑制作用
Rosuvastatin inhibits MMP-2 expression and improves the progression of atherosclerosis in LDLR-deficient mice
摘要
Abstract
Objective To investigate the effects of rosuvastatin on atherosclerosis and the expression of Matrix metalloproteinase- 2 (MMP- 2) in LDLR- deficient (LDLR-/-) mice.Methods Seven weeks old LDLR-/- mice (n=16) were fed on a high- fat and high- cholesterol diet to developed hyperlipoidemia and atherosclerosis.They were randomly divided into rosuvastatin group (n=8), control group (n=8).After 12 weeks they were sacrificed.The atherosclerosis lesion area in aorta artery and aortic sinus was examined.The levels of plasma lipid, glucose and insulin were measured, as well as the expression of MMP- 2 and MMP- 9 in the atherosclerosis plaques.Results Versus control group, except for HDL- C, the levels of plasma TC, TG, LDL- C, oxLDL in the rosuvastatin group were decreased significantly (P＜0.05 or 0.01).Compared to the control group, rosuvastatin reduced the atherosclerosis lesion area by 80％, and rosuvastatin reduced the lesion area by 74.1％ in the aortic sinus.The production of MMP- 2 in the aortic sinus through immunohistochemical method was reduced 45.9％ in rosuvastatin group.The activation of MMP- 2 and MMP- 9 in aorta arch with gelatin zymography was reduced 42.3 ％and 35.3 ％ in rosuvastatin group.Conclusion Rosuvastatin inhibits the expression of MMP- 2/- 9 and improves the progression of atherosclerosis in LDLR-/- mice.This may be one of the pathways of rosuvastatin on atherosclerosis, through which that rosuvastatin induced its benefit to the therapy of coronary heart disease.关键词
瑞舒伐他汀/基质金属蛋白酶/动脉粥样硬化/LDL受体基因缺陷小鼠Key words
Rosuvastatin / Matrix metalloproteinase-2 / Atherosclerosis / LDL receptor deficient mice引用本文复制引用
刘龙斌,史亚非,郭航远,许富康,孙爱静,池菊芳..瑞舒伐他汀对LDL受体基因缺陷小鼠MMP-2表达和粥样斑块形成的抑制作用[J].浙江医学,2011,33(7):1020-1023,1110,5.基金项目
浙江省科技计划项目(2008C33058) （2008C33058）
